NCT03069352 2025-09-30A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAbbViePhase 3 Completed211 enrolled 30 charts 2 FDA
NCT02000427 2024-05-28Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaAmgenPhase 2 Completed45 enrolled 24 charts 1 FDA
NCT02013167 2024-03-05Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Terminated405 enrolled 27 charts 1 FDA
NCT04145531 2023-11-18An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)Jazz PharmaceuticalsPhase 2/3 Completed229 enrolled 17 charts 2 FDA
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT00372593 2021-03-24Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaChildren's Oncology GroupPhase 3 Completed1,070 enrolled 18 charts 2 FDA